Low antibody levels associated with significantly increased rate of SARS-CoV-2 infection in a highly vaccinated population from the US National Basketball Association.
COVID-19
SARS-CoV-2 antibodies
immunity
serology testing
test utilization
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
12
02
2024
received:
23
10
2023
accepted:
23
02
2024
medline:
11
3
2024
pubmed:
11
3
2024
entrez:
11
3
2024
Statut:
ppublish
Résumé
SARS-CoV-2 antibody levels may serve as a correlate for immunity and could inform optimal booster timing. The relationship between antibody levels and protection from infection was evaluated in vaccinated individuals from the US National Basketball Association who had antibody levels measured at a single time point from September 12, 2021, to December 31, 2021. Cox proportional hazards models were used to estimate the risk of infection within 90 days of serologic testing by antibody level (<250, 250-800, and >800 AU/mL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29505Subventions
Organisme : NBA
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407-1416. doi:10.1016/s0140-6736(21)02183-8
Britton A, Fleming-Dutra KE, Shang N, et al. Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and delta variant predominance. JAMA. 2022;327(11):1032. doi:10.1001/jama.2022.2068
Tai CG, Maragakis LL, Connolly S, et al. Association between COVID-19 booster vaccination and omicron infection in a highly vaccinated cohort of players and staff in the National Basketball Association. JAMA. 2022;328(2):209. doi:10.1001/jama.2022.9479
Moreira ED, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386(20):1910-1921. doi:10.1056/nejmoa2200674
Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421-2430. doi:10.1056/nejmoa2115926
Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine. JAMA Intern Med. 2022;182(2):179. doi:10.1001/jamainternmed.2021.7382
Grunau B, Goldfarb DM, Asamoah-Boaheng M, et al. Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals. JAMA. 2022;327(3):279. doi:10.1001/jama.2021.21921
Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022;386(18):1712-1720. doi:10.1056/NEJMoa2201570
US Food and Drug Administration. EUA Authorized Serology Test Performance. Accessed October 31, 2022. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance
US Food and Drug Administration. Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication. Accessed November 1, 2022. https://www.fda.gov/medical-devices/safety-communications/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety
Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032-2040. doi:10.1038/s41591-021-01540-1
Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43-50. doi:10.1126/science.abm3425
US Food and Drug Administration. LIAISON SARS-CoV-2 TrimericS IgG. Accessed November 4, 2022. https://www.fda.gov/media/149060/download
Perkmann T, Mucher P, Ösze D, et al. Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology. J Clin Virol. 2023;158:105345. doi:10.1016/j.jcv.2022.105345
Lavezzo E, Pacenti M, Manuto L, et al. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. Genome Med. 2022;14(1):61. doi:10.1186/s13073-022-01066-2
Bonelli F, Blocki FA, Bunnell T, et al. Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021;59(8):1463-1467. doi:10.1515/cclm-2021-0023
Perkmann T, Perkmann-Nagele N, Koller T, et al. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiol Spectr. 2021;9(1):e00247-21. doi:10.1128/Spectrum.00247-21
Mack CD, Tai C, Sikka R, et al. Severe acute respiratory syndrome coronavirus 2 reinfection: a case series from a 12-month longitudinal occupational cohort. Clin Infect Dis. 2022;74(9):1682-1685. doi:10.1093/cid/ciab738
Mack CD, DiFiori J, Tai CG, et al. SARS-CoV-2 transmission risk among national basketball association players, staff, and vendors exposed to individuals with positive test results after COVID-19 recovery during the 2020 regular and postseason. JAMA Intern Med. 2021;181(7):960. doi:10.1001/jamainternmed.2021.2114
US Food and Drug Administration. LIAISON® SARS-CoV-2 TrimericS IgG (Instructions for Use). Accessed December 19, 2022. https://www.fda.gov/media/149059/download
Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676-681. doi:10.1038/s41586-021-04388-0
Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130-135. doi:10.1038/s41586-021-03398-2
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
Hay JA, Kissler SM, Fauver JR, et al. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: a retrospective cohort study. eLife. 2022;11:e81849. doi:10.7554/eLife.81849
Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N Engl J Med. 2022;386(6):599-601. doi:10.1056/NEJMc2119641
Yu J, Collier AR, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med. 2022;386(16):1579-1580. doi:10.1056/NEJMc2201849
Springer DN, Perkmann T, Jani CM, et al. Reduced sensitivity of commercial spike-specific antibody assays after primary infection with the SARS-CoV-2 Omicron variant. Microbiol Spectr. 2022;10(5):e02129-22. doi:10.1128/spectrum.02129-22
Kwok SL, Cheng SM, Leung JN, et al. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Euro Surveill. 2022;27(2):2101197. doi:10.2807/1560-7917.ES.2022.27.2.2101197
Shrotri M, Fragaszy E, Nguyen V, et al. Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. Nat Commun. 2022;13(1):5780. doi:10.1038/s41467-022-33550-z
Angel-Korman A, Peres E, Bryk G, et al. Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose. Clin Kidney J. 2022;15(2):226-234. doi:10.1093/ckj/sfab206
Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection. JAMA Netw Open. 2022;5(9):e2231778. doi:10.1001/jamanetworkopen.2022.31778
Hatzakis A, Karabinis A, Roussos S, et al. Modelling SARS-CoV-2 binding antibody waning 8 months after BNT162b2 vaccination. Vaccines. 2022;10(2):285. doi:10.3390/vaccines10020285
Garcia L, Woudenberg T, Rosado J, et al. Kinetics of the SARS-CoV-2 antibody avidity response following infection and vaccination. Viruses. 2022;14(7):1491. doi:10.3390/v14071491
Laing ED, Weiss CD, Samuels EC, et al. Durability of antibody response and frequency of SARS-CoV-2 infection 6 months after COVID-19 vaccination in healthcare workers. Emerg Infect Dis. 2022;28(4):828-832. doi:10.3201/eid2804.212037
Sanchez L, Oviedo Rouco S, Pifano M, et al. Antibody durability at 1 year after Sputnik V vaccination. Lancet Infect Dis. 2022;22(5):589-590. doi:10.1016/S1473-3099(22)00176-1
Pérez-Alós L, Armenteros JJA, Madsen JR, et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun. 2022;13(1):1614. doi:10.1038/s41467-022-29225-4
Vicentini C, Zotti CM, Cornio AR, et al. Serological responses up to 9 months following COVID-19 mRNA vaccination in residents and health-care workers of long-term care facilities: a multicenter prospective cohort study in Northern Italy. Vaccines. 2022;10(12):2183. doi:10.3390/vaccines10122183
Rössler A, Knabl L, Raschbichler LM, et al. Reduced sensitivity of antibody tests after omicron infection. Lancet Microbe. 2023;4(1):e10-e11. doi:10.1016/S2666-5247(22)00222-1
US Centers for Disease Control and Prevention. Stay Up to Date with COVID-19 Vaccines Including Boosters. Accessed November 1, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html